

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



TARSONS PRODUCTS LIMITED

Our Company was incorporated as 'Tarsons Products Private Limited' on July 5, 1983, at Kolkata, West Bengal, India as a private limited company under the Companies Act, 1956. Our Company was subsequently converted into a public limited company pursuant to a special resolution passed by our Shareholders at the extraordinary general meeting held on May 10, 2021, and the name of our Company was changed to 'Tarsons Products Limited'. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued on June 14, 2021. For further details of changes in name and Registered and Corporate Office of our Company, see 'History and Certain Corporate Matters' on page 150 of the Red Herring Prospectus dated November 8, 2021 ("RHP").

Registered and Corporate Office: Martin Bum Business Park, Room No. 902 BP- 3, Salt Lake, Sector- V, Kolkata - 700091, West Bengal, India. Tel: +91 33 3522 0300, Website: www.tarsons.com; Contact Person: Piyush Khater, Company Secretary and Compliance Officer; E-mail: piyush@tarsons.in, Corporate Identity Number: U51109WB1983PLC036510

OUR PROMOTERS: SANJIVE SEHGAL AND ROHAN SEHGAL

INITIAL PUBLIC OFFER OF UP TO $\lceil \bullet \rceil$ EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF TARSONS PRODUCTS LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ $\lceil \bullet \rceil$ PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ $\lceil \bullet \rceil$ PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ $\lceil \bullet \rceil$ MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO $\lceil \bullet \rceil$ EQUITY SHARES AGGREGATING UP TO ₹1,500 MILLION BY OUR COMPANY (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 390,000 EQUITY SHARES BY SANJIVE SEHGAL AGGREGATING UP TO ₹ $\lceil \bullet \rceil$ MILLION, UP TO 310,000 EQUITY SHARES BY ROHAN SEHGAL (SANJIVE SEHGAL AND ROHAN SEHGAL AGGREGATING UP TO ₹ $\lceil \bullet \rceil$ MILLION, TOGETHER "PROMOTER SELLING SHAREHOLDERS") AND UP TO 12,500,000 EQUITY SHARES AGGREGATING UP TO ₹ $\lceil \bullet \rceil$ MILLION BY CLEAR VISION INVESTMENT HOLDINGS PTE. LIMITED (THE "INVESTOR SELLING SHAREHOLDER", TOGETHER WITH THE PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS" AND SUCH EQUITY SHARES, THE "OFFERED SHARES") AGGREGATING UP TO ₹ $\lceil \bullet \rceil$ MILLION (THE "OFFER FOR SALE"). THE OFFER INCLUDES A RESERVATION OF UP TO 60,000 EQUITY SHARES, AGGREGATING TO ₹ $\lceil \bullet \rceil$ MILLION (CONSTITUTING UP TO $\lceil \bullet \rceil$ % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS "NET OFFER". THE OFFER AND NET OFFER SHALL CONSTITUTE $\lceil \bullet \rceil$ % AND $\lceil \bullet \rceil$ %, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. *OUR COMPANY AND THE SELLING SHAREHOLDERS IN CONSULTATION WITH THE BRLMs, MAY OFFER A DISCOUNT OF UP TO $\lceil \bullet \rceil$ % OF THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION.

QIB Portion: Not more than 50% of the Net Offer

Retail Portion: Not less than 35% of the Net Offer

Non-Institutional Portion: Not less than 15% of the Net Offer

Employee Reservation Portion : Up to 60,000 Equity Shares

Price Band: ₹ 635 to ₹ 662 per Equity Share of face value of ₹2 each.

A discount of ₹ 61 per Equity Share is being offered to Eligible Employees bidding in the Employee Reservation Portion.

The Floor Price is 317.50 times the face value of the Equity Shares and the Cap Price is 331.00 times the face value of the Equity Shares.

Bids can be made for a minimum of 22 Equity Shares and in multiples of 22 Equity Shares thereafter.

ASBA[#]

Simple, Safe, Smart way of Application!!!

[#] Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, For further details, check section on ASBA below.

Mandatory in public issues. No cheque will be accepted.



UPI-Now available in ASBA for Retail Individual Investors ("RIIs") applying through Registered Brokers, DP's and RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021

ASBA has to be availed by all the investors except Anchor Investors. UPI may be availed by Retail Individual Bidders. For details on the ASBA and UPI process, please refer to the details given in ASBA Form and abridged prospectus and also please refer to the section "Offer Procedure" on page 288 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and the websites of BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"), and together with "BSE", the "Stock Exchanges") and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of "Stock Exchanges" and can be obtained from the list of banks that is displayed on the website of Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in. List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. For the list of UPI Apps and banks live on IPO, please refer to the link: www.sebi.gov.in. RIIs Bidding using the UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=34) and (https://sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40) respectively, as updated from time to time. Axis Bank Limited has been appointed as Sponsor Bank for the Offer, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For offer related queries, please contact the Book Running Lead Managers ("BRLMs") on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and mail id: ipo.upi@npci.org.in, Axis Bank Limited at Tel: 033-22623558 and E-mail: bdbdagh.branchhead@axisbank.com; and the Registrar to the Offer at Tel: (91 40) 6716 2222, 1800 309 4001 and E-mail: tarsonsproducts ipo@kfintech.com.

Risks to Investors

- The 3 BRLMs associated with the Offer have handled 42 public issues in the past three years, out of which 16 issues closed below the offer price on the listing date.
- The Price/Earnings ratio based on a restated consolidated basis for Fiscal 2021 for the Company at the upper end of the Price Band is as high as 49.29 times.
- Average cost of acquisition of Equity Shares held by the Selling Shareholders namely Sanjive Sehgal, Rohan Sehgal and Clear Vision Investment Holdings Pte. Limited is ₹ 1.78, ₹ 0.03, ₹ 51.83 and Offer Price at upper end of the Price Band is ₹ 662 per Equity Share.
- Weighted Average Return on Net Worth for Fiscals 2021, 2020, 2019 is 25.73%.

BASIS FOR OFFER PRICE

The Floor Price, Cap Price and Offer Price will be determined by our Company and Selling Shareholders in consultation with the BRLMs, on the basis of assessment of market demand for the Equity Shares offered through the Book Building Process and on the basis of quantitative and qualitative factors as described below. The face value of the Equity Shares is ₹ 2 each and the Offer Price is 317.50 times the Floor Price and 331 times the Cap Price. Prospective investors should also see "Our Business", "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations", "Financial Statements" and "Summary of Financial Information" on pages 123, 24, 233, 173 and 53, respectively, of the RHP, to have an informed view before making an investment decision.

Qualitative Factors : Some of the qualitative factors and our strengths which form the basis for computing the Offer Price are: • Supplier to life sciences sector with strong brand recognition and quality products; • Range of labware products across varied customer segments; • Operating in an industry which has a large addressable market; • Well-equipped and automated manufacturing facilities; • Geographic reach through our pan India sales and distribution network; • Experienced Promoter backed by strong management team. For details, see "Our Business – Our Strengths" on page 124 of the RHP.

Quantitative Factors : The information presented below relating to our Company is based on the Restated Financial Information for three months ending June 30, 2021 and June 30, 2020 and Fiscals 2021, 2020 and 2019.

For details, see "Financial Statements" on page 173 of the RHP.

Some of the quantitative factors which may form the basis for computing the Offer Price are as follows:

A. Basic and Diluted Earnings Per Share ("EPS"):

Fiscal	Basic EPS (in ₹)	Diluted EPS (in ₹)	Weight
March 31, 2019	7.65	7.50	1
March 31, 2020	7.94	7.75	2
March 31, 2021 ^a	13.43	13.43	3
Weighted Average^a	10.64	10.55	
Three months for the period ended June 30, 2021 ^a	4.88	4.88	

^a Weighted average means weighted average diluted and basic earnings per share ("EPS") derived from Restated Financial Information based on weights assigned for the respective year ended March 31.

^a Pursuant to a resolution passed by our Board on June 14, 2021 and a resolution passed by our Shareholders in the

EGM held on June 16, 2021 our Company has sub-divided its authorised share capital, such that 20,000,000 Equity Shares of ₹10 each aggregating to ₹200,000,000 were sub-divided and reclassified as 10,000,000 Equity Shares of ₹2 each aggregating to ₹200,000,000. Therefore, the cumulative number of issued, subscribed and paid up Equity Shares, pursuant to sub-division was increased from 192,228 Equity Shares of ₹10 each to 961,140 Equity Shares of ₹2 each. Stock split of shares are retrospectively considered for the computation of EPS in accordance with Ind AS 33 for all periods presented.

^a The Board of Directors pursuant to a resolution dated June 14, 2021 and the shareholders pursuant to special resolution dated June 16, 2021 have approved the issuance of 52 bonus shares of face value ₹2 each for every one existing fully paid up equity share of face value ₹2 each and accordingly bonus shares were issued and allotted. Bonus shares are retrospectively considered for the computation of EPS in accordance with Ind AS 33 for all periods presented.

NOTES:

Basic earnings per share (₹) = Restated profit for the year attributable to equity shareholders for calculation of basic EPS
Weighted average number of equity shares in calculating basic EPS

Diluted earnings per share (₹) = Restated profit for the year attributable to equity shareholders for calculation of basic EPS
Weighted average number of diluted equity shares in calculating diluted EPS

Basic and diluted earnings per equity share are computed in accordance with Ind AS 33 'Earnings per share'.

^a Basic EPS and Diluted EPS for the three months ended June 30, 2021 are not annualized

B. Price/Earning ("P/E") ratio in relation to Price Band of ₹ 635 to ₹ 662 per Equity Share:

Particulars	P/E at the Floor Price (no. of times)	P/E at the Cap Price (no. of times)
Based on basic EPS for Fiscal 2021	47.28	49.29
Based on diluted EPS for Fiscal 2021	47.28	49.29

C. Industry Peer Group P/E ratio

There are no listed entities whose business portfolio is comparable with that of our business and comparable to our scale of operations.

FOR FURTHER DETAILS, SEE "BASIS FOR OFFER PRICE" BEGINNING ON PAGE 84 OF THE RHP.

D. Return on Net worth

Fiscal	RoNW (in %)	Weight
March 31, 2019	28.80	1
March 31, 2020	20.51	2
March 31, 2021	28.19	3
Weighted Average^a	25.73	
Three months ended June 30, 2021	9.23	

^a Weighted average means weighted average return on net worth derived from Restated Financial Information based on weights assigned for the respective year ended March 31.

NOTES: 1. Return on Net Worth (%) = Net profit after tax before other comprehensive income (as restated) divided by net worth at the end of the year/period. 2. Net worth has been computed as sum of paid up share capital and other equity. 3. Return on Net Worth for the three months ended June 30, 2021 is not annualized

E. Net Asset Value ("NAV") per share:

Fiscal/ Period ended	NAV (₹)
As on March 31, 2021	47.65
As on June 30, 2021	52.80
After the completion of the Offer	At the Floor Price: 78.60 At the Cap Price: 78.74
Offer Price	$\lceil \bullet \rceil$

NOTES: 1. NAV per Equity Share = Net worth at the end of the year / Number of equity shares outstanding (without impact of effect of dilutive potential equity shares) during the year after considering the impact of bonus and sub-divided shares.

F. Comparison with Listed Industry Peers

There are no listed entities whose business portfolio is comparable with that of our business and comparable to our scale of operations.

G. The Offer price is $\lceil \bullet \rceil$ times of the face value of the Equity Shares

The Offer Price of ₹ $\lceil \bullet \rceil$ has been determined by our Company and Selling Shareholders in consultation with the BRLMs, on the basis of market demand from investors for Equity Shares through the Book Building Process.

Investors should read the above mentioned information along with "Risk Factors", "Our Business", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Financial Statements" on pages 24, 123, 233 and 173, respectively, of the RHP, to have a more informed view.

BID/ OFFER SCHEDULE

BID/OFFER OPENS ON : MONDAY, NOVEMBER 15, 2021*

BID/OFFER CLOSES ON : WEDNESDAY, NOVEMBER 17, 2021^a

* Our Company and the Selling Shareholders, in consultation with the BRLMs, may consider participation by Anchor Investors in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"). The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date i.e. Friday, November 12, 2021.

^a UPI Mandate end time and date shall be at 12:00 pm on Thursday, November 18, 2021.

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least 3 additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Selling Shareholders may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of 3 Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to the Designated Intermediaries and the Sponsor Bank.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion") provided that our Company and the Selling Shareholders, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds only, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts and UPI ID (in case of RIIs), if applicable, in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Bank under the UPI Mechanism, as applicable. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 288 of the RHP.

Bidders/Applicants should ensure that DP ID, PAN, Client ID and UPI ID (for RIIs bidding through the UPI mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID (for RIIs bidding through the UPI mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorised the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the

Demographic Details would be at the Bidders/Applicants' sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021.

Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects of the Company, please see the section "History and Certain Corporate Matters" on page 150 of the RHP and Clause III (A) 1 of the Memorandum of Association of the Company. The Memorandum of Association of the Company is a material document for inspection in relation to the Offer. For further details, please see the section entitled "Material Contracts and Documents for Inspection" on page 317 of the RHP.

Liability of the members of the Company: Limited by shares

Amount of share capital of the Company and Capital structure: As on the date of the RHP, the Authorised share capital of the Company is ₹ 200,000,000 divided into 100,000,000 equity shares of face value of ₹ 2 each. The issued, subscribed and paid-up share capital of the Company is ₹ 101,880,840 divided into 50,940,420 equity shares of face value of ₹2 each. For details, please see the section entitled "Capital Structure" on page 65 of the RHP.

Names of Initial signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them: The names of the signatories of the Memorandum of Association of our Company are Jyoti Sehgal, Atul Sehgal and Sanjive Sehgal subscribed 10 equity shares each. For details of the share capital history and capital structure of our Company, please see the section entitled "Capital Structure" on page 65 of the RHP.

Listing: The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to their letters dated September 7, 2021 and September 8, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be BSE Limited. A signed copy of the Draft Red Herring Prospectus has been filed and signed copy of the Red Herring Prospectus and the Prospectus shall be filed with the RoC in accordance with Sections 26(4) and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus up to the Bid/Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 317 of the RHP.

Disclaimer Clause of the SEBI: SEBI only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 270-271 of the RHP for the full text of the disclaimer clause of SEBI.

Disclaimer Clause of NSE : It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 272 of the RHP for the full text of the disclaimer clause of NSE.

Disclaimer Clause of BSE (Designated Stock Exchange) : It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the RHP has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 272 of the RHP for the full text of the disclaimer clause of BSE.

General Risks: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 24 of the RHP.

BOOK RUNNING LEAD MANAGERS TO THE OFFER			REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
				Piyush Khater Martin Bum Business Park, Room No. 902 BP- 3, Salt Lake, Sector- V, Kolkata 700091, West Bengal, India Tel: +91 33 3522 0285 E-mail: piyush@tarsons.in
ICICI Securities Limited ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India Tel: (91 22) 68077100 E-mail: tarsons.ipo@icicisecurities.com Website: www.icicisecurities.com Investor Grievance e-mail: customercare@icicisecurities.com Contact Person: Rupesh Khant/ Kristina Dias SEBI Registration Number: INM000011179	Edelweiss Financial Services Limited 6 th floor, Edelweiss House, Off C.S.T. Road, Kalina, Mumbai - 400 098, India Tel: (91 22) 4009 4400 E-mail: tarsons.ipo@edelweissfn.com Website: www.edelweissfn.com Investor Grievance e-mail: customerservice.mh@edelweissfn.com Contact Person: Dhruv Bhavsar SEBI Registration Number: INM0000010650	SBI Capital Markets Limited 202, Maker Tower 'E', Cuffe Parade, Mumbai - 400 005, India Tel: (91 22) 2217 8300 E-mail: tarsons.ipo@sbicaps.com Website: www.sbicaps.com Investor Grievance e-mail: investorrelations@sbicaps.com Contact Person: Karan Savardekar / Sambit Rath SEBI Registration Number: INM000003531	KFin Technologies Private Limited (formerly known as Karry Fintech Private Limited) Selenium Tower-B, Plot 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Telangana - 500032, India Tel: (91 40) 6716 2222, 1800 309 4001 E-mail: tarsonsproducts.ipo@kfintech.com Investor Grievance e-mail: Einward.rs@kfintech.com Website: www.kfintech.com Contact Person: M. Murali Krishna SEBI Registration Number: INM000000221	Investors can contact our Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-Offer or post-Offer related problems such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all Offer related queries and for redressal of complaints, investors may also write to the BRLMs

AVAILABILITY OF THE RHP: Investors are advised to refer to the RHP and the Risk Factors, contained therein before applying in the Offer. A copy of the RHP is available on website of SEBI at www.sebi.gov.in, websites of the BRLMs, i.e. ICICI Securities Limited, Edelweiss Financial Services Limited and SBI Capital Markets Limited at www.icicisecurities.com, www.edelweissfn.com and www.sbicaps.com, respectively and on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com, respectively.

AVAILABILITY OF BID CUM APPLICATION FORMS: Bid cum Application Forms can be obtained from the Registered Office of TARSONS PRODUCTS LIMITED, Tel: +91 33 3522 0300. BRLMs : ICICI Securities Limited, Tel: (91 22) 68077100, Edelweiss Financial Services Limited, Tel: (91 22) 4009 4400 and SBI Capital Markets Limited, Tel: (91 22) 2217 8300 and Syndicate Members : Edelweiss Securities Limited, Tel: +91 22 40635569, SBICAP Securities Limited, Tel: +91 22 4227 3300, Investec Capital Services (India) Private Limited, Tel: +91 22 6849 7400, at the select locations of the Sub-syndicate Members (as given below), SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. ASBA Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

Sub-Syndicate Members: Anand Rath Share & Stock Brokers Limited, Axis Capital Limited, Centrum Broking Limited, Choice Equity Broking Private Limited, DB(International) Stock Brokers Limited, Edelweiss Broking Limited, Eureka Stock & Share Broking Services Limited, IDBI Capital Markets & Securities Limited, J M Financial Services Limited, Jobanputra Fiscal Services Private Limited, Kotak Securities Limited, LKP Securities Limited, Inventure Growth & Securities Limited, Motilal Oswal Financial Services Limited, Prabhudas Ladhani Private Limited, Pravin Ratilal Share and Stock Brokers Limited, RR Equity Brokers Private Limited, Sharekhan Limited, SMC Global Securities Limited, Systematic Shares and Stocks (India) Limited, Trade Bulls Securities (P) Limited and Way2wealth brokers Private Limited

Escrow Collection Bank(s)/ Public Offer Account Bank / Refund Bank / Sponsor Bank: Axis Bank Limited

UPI: Retail Individual Investors can also Bid through UPI mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

Place: Kolkata
Date: November 09, 2021

TARSONS PRODUCTS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with Registrar of Companies, West Bengal at Kolkata on November 8, 2021. The RHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e. ICICI Securities Limited, Edelweiss Financial Services Limited and SBI Capital Markets Limited at www.icicisecurities.com, www.edelweissfn.com and www.sbicaps.com, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled "Risk Factors" on page 24 of the RHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933 (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S and the applicable laws of each jurisdictions where such offers and sales are made. There will be no public offering of the Equity Shares in the United States.

For TARSONS PRODUCTS LIMITED
On behalf of the Board of Directors
Sd/-
Company Secretary and Compliance Officer